In the service of life
The need for information on the molecular level is growing. Machines run sequencing processes 24/7. That’s one of the reasons Battmann picked the GeneReader NGS System in 2016, a technology which he believes has made its mark on cancer research, and will continue to do so for the next 15 to 20 years. Why? “Because it gets the most comprehensive set of data you can get,” says Battmann, referring to the report generated by the system via integrated QIAGEN Clinical Insight (QCI) Interpret bioinformatics software.
The data report includes information like the kind of mutation, and the potential pathogenic impact of the mutation on the disease. “And if you want to dive further into this, it seems like there is always a list of citations on everything.”
These vast amounts of data have given rise to another issue that is gaining importance. Battmann calls it “a controlled reproducible workflow”. One of the QIAGEN GeneReader NGS System’s most important benefits is its ability to bundle the whole process in a single workflow, because switching between systems can spur mistakes.
Besides the workflow, QIAGEN’s service swayed him: “The most advanced instrument is of no use if there is no service provided.” Battmann's experience with QIAGEN is: “They meet all our demands. We just order the things, and they come. If there’s a problem we call and it’s taken care of.”
Watch what others have to say